Association between triglyceride‑glucose index as a marker of insulin resistance and the risk of malignant melanoma: A retrospective study

Sun,Jiukang; Han,Zhihang; Song,Chuanjun

doi:10.3892/ol.2025.14919

Association between triglyceride‑glucose index as a marker of insulin resistance and the risk of malignant melanoma: A retrospective study

Authors:
- Jiukang Sun
- Zhihang Han
- Chuanjun Song
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai 201499, P.R. China, Department of Oncology, Xinghua People's Hospital Affiliated to Yangzhou University, Xinghua, Jiangsu 225700, P.R. China
Published online on: February 7, 2025 https://doi.org/10.3892/ol.2025.14919
Article Number: 173
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma, a highly malignant tumor predominantly found on the skin surface, has exhibited an alarming rise in both incidence and mortality rates annually since 2012. Despite its relatively low occurrence among skin malignancies, the mortality rate of malignant melanoma remains disproportionately high. The prognosis relies heavily on early stage detection, with a significant disparity in survival rates between stage I and stage IV patients. Studies exploring insulin resistance (IR) as a potential risk factor for malignant melanoma are scarce. The present study therefore investigated the association between the triglyceride glucose (TyG) index, an indicator of IR, and malignant melanoma incidence. Retrospective data from patients diagnosed with malignant melanoma at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China) between January 2019 and January 2024 were collected. Basic information, including age, sex and body mass index, and hematological test results, such as those for fasting triglycerides and fasting blood glucose, were analyzed. Logistic regression analysis and receiver operating characteristic (ROC) curve analysis were employed to explore the association between melanoma risk and the TyG index. A total of 403 participants, including 272 patients with malignant melanomas and 131 patients with nevi, were included in the study. The melanoma group exhibited significantly higher levels of the TyG index compared with the control group (P<0.001). Univariate and multivariable logistic regression analyses revealed the TyG index as an independent risk factor for melanoma incidence (OR, 6.33; 95% CI, 3.56‑11.27; P<0.001). Incidence rates of melanoma significantly increased across tertiles of the TyG index (P<0.001). The ROC curve analysis identified a clinically acceptable predictive cutoff point for the TyG index. The present study therefore provides evidence that the TyG index is a significant risk factor for the incidence of malignant melanoma. The findings underscore the potential utility of the TyG index as a biomarker for diagnosing melanoma and suggest new avenues for melanoma treatment strategies.

View Figures

View References

1	Raimondi S, Suppa M and Gandini S: Melanoma epidemiology and sun exposure. Acta Derm Venereol. 100:adv001362020. View Article : Google Scholar : PubMed/NCBI
2	Waseh S and Lee JB: Advances in melanoma: Epidemiology, diagnosis, and prognosis. Front Med (Lausanne). 10:12684792023. View Article : Google Scholar : PubMed/NCBI
3	Eisemann N, Schumann L, Baltus H, Labohm L, Kraywinkel K and Katalinic A: Longer survival from melanoma in Germany. Dtsch Arztebl Int. 121:45–51. 2024.PubMed/NCBI
4	Toussi A, Mans N, Welborn J and Kiuru M: Germline mutations predisposing to melanoma. J Cutan Pathol. 47:606–616. 2020. View Article : Google Scholar : PubMed/NCBI
5	Holly EA, Kelly JW, Shpall SN and Chiu SH: Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol. 17:459–468. 1987. View Article : Google Scholar : PubMed/NCBI
6	Fears TR, Scotto J and Schneiderman MA: Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. Am J Epidemiol. 105:420–427. 1977. View Article : Google Scholar : PubMed/NCBI
7	Chen S, Chen Y, Liu X, Li M, Wu B, Li Y, Liang Y, Shao X, Holthöfer H and Zou H: Insulin resistance and metabolic syndrome in normal-weight individuals. Endocrine. 46:496–504. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G and Fargion S: Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology. 48:792–798. 2008. View Article : Google Scholar : PubMed/NCBI
9	Czech MP: Mechanisms of insulin resistance related to white, beige, and brown adipocytes. Mol Metab. 34:27–42. 2020. View Article : Google Scholar : PubMed/NCBI
10	Yan X, Gao Y, Tong J, Tian M, Dai J and Zhuang Y: Association between triglyceride glucose index and non-small cell lung cancer risk in Chinese population. Front Oncol. 11:5853882021. View Article : Google Scholar : PubMed/NCBI
11	Panigoro SS, Sutandyo N, Witjaksono F, Siregar NC, Ramli R, Hariani R, Pangarsa EA, Prajoko YW, Puruhita N, Hamdani W, et al: The association between triglyceride-glucose index as a marker of insulin resistance and the risk of breast cancer. Front Endocrinol (Lausanne). 12:7452362021. View Article : Google Scholar : PubMed/NCBI
12	Alkurt EG, Şahin F, Tutan B, Canal K and Turhan VB: The relationship between papillary thyroid cancer and triglyceride/glucose index, which is an indicator of insulin resistance. Eur Rev Med Pharmacol Sci. 26:6114–6120. 2022.PubMed/NCBI
13	Li W, Liu T, Qian L, Wang Y, Ma X, Cao L, Zhang Q and Qu J: Insulin resistance and inflammation mediate the association of abdominal obesity with colorectal cancer risk. Front Endocrinol (Lausanne). 13:9831602022. View Article : Google Scholar : PubMed/NCBI
14	DeFronzo RA, Tobin JD and Andres R: Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 237:E214–E223. 1979.PubMed/NCBI
15	Sánchez-García A, Rodríguez-Gutiérrez R, Mancillas-Adame L, González-Nava V, Díaz González-Colmenero A, Solis RC, Álvarez-Villalobos NA and González-González JG: Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: A systematic review. Int J Endocrinol. 2020:46785262020. View Article : Google Scholar : PubMed/NCBI
16	Rohm TV, Meier DT, Olefsky JM and Donath MY: Inflammation in obesity, diabetes, and related disorders. Immunity. 55:31–55. 2022. View Article : Google Scholar : PubMed/NCBI
17	Kim DS and Scherer PE: Obesity, diabetes, and increased cancer progression. Diabetes Metab J. 45:799–812. 2021. View Article : Google Scholar : PubMed/NCBI
18	Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V and Orekhov AN: The diabetes mellitus-atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 21:18352020. View Article : Google Scholar : PubMed/NCBI
19	Gado M, Tsaousidou E, Bornstein SR and Perakakis N: Sex-based differences in insulin resistance. J Endocrinol. 261:e2302452024. View Article : Google Scholar : PubMed/NCBI
20	Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, et al: Alcohol consumption and site-specific cancer risk: A comprehensive dose-response meta-analysis. Br J Cancer. 112:580–593. 2015. View Article : Google Scholar : PubMed/NCBI
21	Saladi RN, Nektalova T and Fox JL: Induction of skin carcinogenicity by alcohol and ultraviolet light. Clin Exp Dermatol. 35:7–11. 2010. View Article : Google Scholar : PubMed/NCBI
22	Xu J, Liu W, Liu X, Zhou X and Li G: Alcohol drinking, smoking, and cutaneous melanoma risk: Mendelian randomization analysis. Gac Sanit. 37:1023512023. View Article : Google Scholar : PubMed/NCBI
23	Gandini S, Masala G, Palli D, Cavicchi B, Saieva C, Ermini I, Baldini F, Gnagnarella P and Caini S: Alcohol, alcoholic beverages, and melanoma risk: A systematic literature review and dose-response meta-analysis. Eur J Nutr. 57:2323–2332. 2018. View Article : Google Scholar : PubMed/NCBI
24	Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1595–1607. 1988. View Article : Google Scholar : PubMed/NCBI
25	Pan K, Chlebowski RT, Mortimer JE, Gunter MJ, Rohan T, Vitolins MZ, Adams-Campbell LL, Ho GYF, Cheng TD and Nelson RA: Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the women's health initiative. Cancer. 126:3638–3647. 2020. View Article : Google Scholar : PubMed/NCBI
26	Qin G, Sun Z, Jin Y, Ren X, Zhang Z, Wang S, Zhou G, Huang K, Zhao H and Jiang X: The association between the triglyceride-glucose index and prognosis in postoperative renal cell carcinoma patients: A retrospective cohort study. Front Endocrinol (Lausanne). 15:13017032024. View Article : Google Scholar : PubMed/NCBI
27	Zhang AMY, Wellberg EA, Kopp JL and Johnson JD: Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 45:285–311. 2021. View Article : Google Scholar : PubMed/NCBI
28	Lien EC, Lyssiotis CA and Cantley LC: Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer. Recent Results Cancer Res. 207:39–72. 2016. View Article : Google Scholar : PubMed/NCBI
29	Belfiore A, Frasca F, Pandini G, Sciacca L and Vigneri R: Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 30:586–623. 2009. View Article : Google Scholar : PubMed/NCBI
30	Zhang AMY, Magrill J, de Winter TJJ, Hu X, Skovsø S, Schaeffer DF, Kopp JL and Johnson JD: Endogenous hyperinsulinemia contributes to pancreatic cancer development. Cell Metab. 30:403–404. 2019. View Article : Google Scholar : PubMed/NCBI
31	Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J and Albanes D: Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 294:2872–2878. 2005. View Article : Google Scholar : PubMed/NCBI
32	Lv Z and Guo Y: Metformin and its benefits for various diseases. Front Endocrinol (Lausanne). 11:1912020. View Article : Google Scholar : PubMed/NCBI
33	Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
34	Podhorecka M, Ibanez B and Dmoszyńska A: Metformin-its potential anti-cancer and anti-aging effects. Postepy Hig Med Dosw (Online). 71:170–175. 2017. View Article : Google Scholar : PubMed/NCBI
35	Vallianou NG, Evangelopoulos A and Kazazis C: Metformin and cancer. Rev Diabet Stud. 10:228–235. 2023. View Article : Google Scholar : PubMed/NCBI
36	Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A and Vigneri R: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 19:3278–3288. 1999. View Article : Google Scholar : PubMed/NCBI
37	Zhong W, Wang X, Wang Y, Sun G, Zhang J and Li Z: Obesity and endocrine-related cancer: The important role of IGF-1. Front Endocrinol (Lausanne). 14:10932572023. View Article : Google Scholar : PubMed/NCBI
38	Wang S, Wang N, Yu B, Cao M, Wang Y, Guo Y, Zhang Y, Zhang P, Yu X, Wang S, et al: Circulating IGF-1 promotes prostate adenocarcinoma via FOXO3A/BIM signaling in a double-transgenic mouse model. Oncogene. 38:6338–6353. 2019. View Article : Google Scholar : PubMed/NCBI
39	Yakar S, Pennisi P, Zhao H, Zhang Y and LeRoith D: Circulating IGF-1 and its role in cancer: Lessons from the IGF-1 gene deletion (LID) mouse. Novartis Found Symp. 262:3–18. 265–268. 2004. View Article : Google Scholar : PubMed/NCBI
40	Malaguarnera R, Sacco A, Voci C, Pandini G, Vigneri R and Belfiore A: Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway. Endocrinology. 153:2152–2163. 2012. View Article : Google Scholar : PubMed/NCBI
41	Ortega-Molina A and Serrano M: PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab. 24:184–189. 2013. View Article : Google Scholar : PubMed/NCBI
42	Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, et al: A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition. Cancer Res. 74:15–23. 2014. View Article : Google Scholar : PubMed/NCBI
43	Chen J, Zhang XD and Proud C: Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice. Sci Signal. 8:pe12015. View Article : Google Scholar : PubMed/NCBI
44	Wang XL, Zhang L, Youker K, Zhang MX, Wang J, LeMaire SA, Coselli JS and Shen YH: Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase. Diabetes. 55:2301–2310. 2006. View Article : Google Scholar : PubMed/NCBI
45	Yu J, Shen J, Sun TT, Zhang X and Wong N: Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 23:483–491. 2013. View Article : Google Scholar : PubMed/NCBI
46	Leachman SA, Lucero OM, Sampson JE, Cassidy P, Bruno W, Queirolo P and Ghiorzo P: Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 36:77–90. 2017. View Article : Google Scholar : PubMed/NCBI
47	Olefsky JM and Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 72:219–246. 2010. View Article : Google Scholar : PubMed/NCBI
48	Kershaw EE and Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 89:2548–2556. 2004. View Article : Google Scholar : PubMed/NCBI
49	Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C and Pratley RE: Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 9:414–417. 2001. View Article : Google Scholar : PubMed/NCBI
50	Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
51	Gonullu G, Ersoy C, Ersoy A, Evrensel T, Basturk B, Kurt E, Oral B, Gokgoz S and Manavoglu O: Relation between insulin resistance and serum concentrations of IL-6 and TNF-alpha in overweight or obese women with early stage breast cancer. Cytokine. 31:264–269. 2005. View Article : Google Scholar : PubMed/NCBI
52	Wu CT, Chen MF, Chen WC and Hsieh CC: The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 8:1592013. View Article : Google Scholar : PubMed/NCBI
53	Bulló M, García-Lorda P, Peinado-Onsurbe J, Hernández M, Del Castillo D, Argilés JM and Salas-Salvadó J: TNFalpha expression of subcutaneous adipose tissue in obese and morbid obese females: Relationship to adipocyte LPL activity and leptin synthesis. Int J Obes Relat Metab Disord. 26:652–658. 2002. View Article : Google Scholar : PubMed/NCBI
54	Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 90:2312–2316. 2004. View Article : Google Scholar : PubMed/NCBI
55	Cruceriu D, Baldasici O, Balacescu O and Berindan-Neagoe I: The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: Molecular insights and therapeutic approaches. Cell Oncol (Dordr). 43:1–18. 2020. View Article : Google Scholar : PubMed/NCBI
56	Pfalzer AC, Leung K, Crott JW, Kim SJ, Tai AK, Parnell LD, Kamanu FK, Liu Z, Rogers G, Shea MK, et al: Incremental elevations in TNFα and IL6 in the human colon and procancerous changes in the mucosal transcriptome accompany adiposity. Cancer Epidemiol Biomarkers Prev. 27:1416–1423. 2018. View Article : Google Scholar : PubMed/NCBI
57	Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K and Ortiz-Urda S: Melanoma risk during immunomodulating treatment. Melanoma Res. 32:411–418. 2022. View Article : Google Scholar : PubMed/NCBI
58	Molinelli E, Ceccarelli G, Fantone S, Di Mercurio E, Gambini D, Maurizi A, Perugini J, Tossetta G, Brisigotti V, De Simoni E, et al: Melanoma and subcutaneous adipose tissue: Role of peritumoral adipokines in disease characterization and prognosis. Pigment Cell Melanoma Res. 36:423–430. 2023. View Article : Google Scholar : PubMed/NCBI
59	Sims EK, Carr ALJ, Oram RA, DiMeglio LA and Evans-Molina C: 100 Years of insulin: Celebrating the past, present and future of diabetes therapy. Nat Med. 27:1154–1164. 2021. View Article : Google Scholar : PubMed/NCBI